Ovarian Cancer Drug Shows Promise

Wednesday, 12 Jun 2013 12:01 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
 
The company said the drug had met its primary goal in the trial, which is the first of three for the new treatment.
 
Amgen said that while it was working on the primary analysis of overall survival for 2014, it saw a favorable survival trend in an interim analysis.
 
Shares in Amgen were up slightly $98.25 in Nasdaq morning trading.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Are Generic Drugs Dangerous?

Tuesday, 23 Sep 2014 09:50 AM

Generic drugs have long been promoted as cost-effective alternatives to brand-name meds. But widespread manufacturing ir . . .

Women Should Be Screened for 'Silent' STDs: Task Force

Tuesday, 23 Sep 2014 08:01 AM

All sexually active women should be screened for two of the most common sexually transmitted infections: chlamydia and g . . .

Plane Travel After Heart Attack Is Safe: Study

Monday, 22 Sep 2014 17:11 PM

People who have a heart attack while traveling abroad may be able to safely fly home on a regular commercial flight, acc . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved